Format

Send to

Choose Destination
Blood. 2018 Jan 11;131(2):263-265. doi: 10.1182/blood-2017-06-790121. Epub 2017 Nov 2.

Efficacy and safety of ruxolitinib in regularly transfused patients with thalassemia: results from a phase 2a study.

Author information

1
Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
2
Department of Pediatric Hematology and Oncology, Istanbul University, Istanbul Medical Faculty, Istanbul, Turkey.
3
Università di Milano, Ca Granda Foundation Istituto di Ricovero e Cura a Carattere Scientifico, Milan, Italy.
4
Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
5
First Department of Pediatrics, University of Athens, Athens, Greece.
6
Campus of Haematology Franco e Piera Cutino Azienda Ospedaliera Ospedali Riuniti Villa Sofia V. Cervello, Palermo, Italy.
7
Department of Pediatrics, Division of Hematology, Children's Hospital of Philadelphia, Philadelphia, PA.
8
Novartis Pharma AG, Basel, Switzerland.
9
Novartis Pharma S.A.S., Rueil Malmaison, France.
10
Novartis Pharmaceuticals Corporation, East Hanover, NJ; and.
11
Ege University Hospital, Department of Pediatric Hematology and Oncology, Izmir, Turkey.
PMID:
29097381
PMCID:
PMC5757682
DOI:
10.1182/blood-2017-06-790121
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center